Sign In
Buy AXGN
$42.21
+0.86 (+2.08%)
At Close: Jul 31, 2026
AxoGen, Inc (NASDAQ:AXGN) Shares Sold by UBS Asset Management Americas Inc.
10:20am, Monday, 13'th Apr 2020
UBS Asset Management Americas Inc. reduced its position in AxoGen, Inc (NASDAQ:AXGN) by 11.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. T
Is AxoGen, Inc.'s (NASDAQ:AXGN) CEO Being Overpaid?
01:21pm, Sunday, 12'th Apr 2020
Karen Zaderej has been the CEO of AxoGen, Inc. (NASDAQ:AXGN) since 2011. This analysis aims first to contrast CEO...
Macquarie Group Ltd. Sells 3,665 Shares of AxoGen, Inc (NASDAQ:AXGN)
10:22am, Sunday, 12'th Apr 2020
Macquarie Group Ltd. cut its holdings in AxoGen, Inc (NASDAQ:AXGN) by 5.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm ow
BidaskClub Downgrades AxoGen (NASDAQ:AXGN) to Sell
08:58am, Saturday, 11'th Apr 2020
AxoGen (NASDAQ:AXGN) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday, BidAskClub reports. Several other equi
Contrasting Stereotaxis (OTCMKTS:STXS) & AxoGen (OTCMKTS:AXGN)
07:18am, Saturday, 11'th Apr 2020
AxoGen (NASDAQ:AXGN) and Stereotaxis (OTCMKTS:STXS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividen
Credit Suisse AG Reduces Stake in AxoGen, Inc (NASDAQ:AXGN)
10:24am, Wednesday, 08'th Apr 2020
Credit Suisse AG lowered its stake in shares of AxoGen, Inc (NASDAQ:AXGN) by 8.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission.
Bank of New York Mellon Corp Sells 121,520 Shares of AxoGen, Inc (NASDAQ:AXGN)
09:30am, Wednesday, 08'th Apr 2020
Bank of New York Mellon Corp reduced its stake in AxoGen, Inc (NASDAQ:AXGN) by 12.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange
AxoGen (NASDAQ:AXGN) versus SpectraScience (NASDAQ:SCIE) Financial Review
06:18am, Wednesday, 08'th Apr 2020
AxoGen (NASDAQ:AXGN) and SpectraScience (OTCMKTS:SCIE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings,
-$0.14 EPS Expected for AxoGen, Inc (NASDAQ:AXGN) This Quarter
08:56am, Monday, 06'th Apr 2020
Equities research analysts expect that AxoGen, Inc (NASDAQ:AXGN) will announce earnings of ($0.14) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estima
Advisors Asset Management Inc. Decreases Position in AxoGen, Inc (NASDAQ:AXGN)
08:06am, Sunday, 05'th Apr 2020
Advisors Asset Management Inc. reduced its position in shares of AxoGen, Inc (NASDAQ:AXGN) by 25.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and E
AxoGen, Inc (NASDAQ:AXGN) Expected to Announce Quarterly Sales of $27.05 Million
06:52am, Sunday, 05'th Apr 2020
Wall Street brokerages predict that AxoGen, Inc (NASDAQ:AXGN) will report sales of $27.05 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided est
AxoGen, Inc (NASDAQ:AXGN) Shares Purchased by Bank of America Corp DE
09:14am, Friday, 03'rd Apr 2020
Bank of America Corp DE increased its position in shares of AxoGen, Inc (NASDAQ:AXGN) by 13.7% during the 4th quarter, Holdings Channel.com reports. The fund owned 873,582 shares of the medical equipm
AxoGen, Inc (NASDAQ:AXGN) Short Interest Up 7.0% in March
08:36am, Friday, 03'rd Apr 2020
AxoGen, Inc (NASDAQ:AXGN) was the target of a large growth in short interest in the month of March. As of March 13th, there was short interest totalling 1,625,900 shares, a growth of 7.0% from the Feb
's Top Upgrades, Downgrades For April 2, 2020
01:35pm, Thursday, 02'nd Apr 2020
Upgrades
Credit Suisse changed the rating for MPLX LP (NYSE: MPLX) from Neutral to Outperform. For the fourth quarter, MPLX had an EPS of $0.58, compared to year-...
Morgan Stanley likes Bristol-Myers Squibb in premarket analyst action
11:20am, Thursday, 02'nd Apr 2020
Exact Sciences (NASDAQ:EXAS) initiated with an Outperform rating and a $70 (25% upside) price target at Evercore ISI.Health Catalyst (NASDAQ:HCAT) initiated with a Buy rating and a $40 (47% upside) pr
